Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: A single-institution experience

Journal of Clinical Oncology

Volumn 29, Issue 28, 2011, Pages 3739-3746

  Arun, Banu ^a   Bayraktar, Soley ^a   Liu, Diane D ^a   Gutierrez Barrera, Angelica M ^a   Atchley, Deann ^a   Pusztai, Lajos ^a   Litton, Jennifer Keating ^a   Valero, Vicente ^a   Meric Bernstam, Funda ^a   Hortobagyi, Gabriel N ^a   Albarracin, Constance ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; ONCOGENE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENES, BRCA1; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 80053595196     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.2682     Document Type: Article

References (46)

1. Kwon JS, Gutierrez-Barrera AM, Young D, et al: Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28:4214-4220, 2010
2. Begg CB, Haile RW, Borg A, et al: Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299:194-201, 2008
3. Szabo CI, King MC: Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60:1013-1020, 1997 (Pubitemid 27194085)
4. Rebbeck TR, Domchek SM: Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 10:108, 2008
5. Risch HA, McLaughlin JR, Cole DE, et al: Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694-1706, 2006 (Pubitemid 44942707)
6. Musolino A, Bella MA, Bortesi B, et al: BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study. Breast 16:280-292, 2007 (Pubitemid 46796852)
7. Byrski T, Gronwald J, Huzarski T, et al: Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 108:289-296, 2008 (Pubitemid 351311366)
8. Chang J, Elledge RM: Clinical management of women with genomic BRCA1 and BRCA2 mutations. Breast Cancer Res Treat 69:101-113, 2001 (Pubitemid 33079017)
9. Kennedy RD, Quinn JE, Mullan PB, et al: The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659-1668, 2004 (Pubitemid 39585635)
10. Lakhani SR, Jacquemier J, Sloane JP, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138-1145, 1998 (Pubitemid 28380718)
11. Hedenfalk I, Duggan D, Chen Y, et al: Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539-548, 2001 (Pubitemid 32167867)
12. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005 (Pubitemid 40559006)
13. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917, 2005 (Pubitemid 40559005)
14. McCabe N, Turner NC, Lord CJ, et al: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66:8109-8115, 2006 (Pubitemid 44299177)
15. Abbott DW, Freeman ML, Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 90:978-985, 1998 (Pubitemid 28340438)
16. Husain A, He G, Venkatraman ES, et al: BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58:1120-1123, 1998 (Pubitemid 28183195)
17. Bhattacharyya A, Ear US, Koller BH, et al: The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899-23903, 2000 (Pubitemid 30624678)
18. Ren Q, Potoczek MB, Krajewski S, et al: Transcriptional regulation of the Bcl-2 gene by wild type BRCA1 is important in regulating response to DNA damage-induced apoptosis. Proc Am Assoc Cancer Res 42:2991, 2001 (abstr 42)
19. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999 (Pubitemid 29075229)
20. Sataloff DM, Mason BA, Prestipino AJ, et al: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 180:297-306, 1995
21. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998 (Pubitemid 28363030)
22. Edge SB, Byrd DR, Compton CC, et al (eds): AJCC Cancer Staging Manual (ed 7). New York, NY, Springer, 2010
23. The World Health Organization Histological Typing of Breast Tumors: Second edition - The World Organization. Am J Clin Pathol 78:806-816, 1982
24. Black MM, Speer FD: Nuclear structure in cancer tissues. Surg Gynecol Obstet 105:97-102, 1957
25. Atchley DP, Albarracin CT, Lopez A, et al: Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282-4288, 2008
26. Chappuis PO, Goffin J, Wong N, et al: A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 39:608-610, 2002 (Pubitemid 34864568)
27. Delaloge S, Pautrier P, Kloos I, et al: BRCA1-linked breast cancer is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. Presented at the 27th Congress of the European Society for Medical Oncology, Nice, France, October 18-22, 2002
28. Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379, 2010
29. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007 (Pubitemid 46698581)
30. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281, 2008
31. Buzdar AU, Valero V, Ibrahim NK, et al: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-233, 2007 (Pubitemid 46121873)
32. Porter DE, Dixon M, Smyth E, et al: Breast cancer survival in BRCA1 carriers. Lancet 341:184-185, 1993 (Pubitemid 23029347)
33. Veronesi A, de Giacomi C, Magri MD, et al: Familial breast cancer: Characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer 5:70, 2005
34. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115-123, 2007 (Pubitemid 47057729)
35. Moller P, Evans DG, Reis MM, et al: Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer 121:1017-1020, 2007 (Pubitemid 47101637)
36. Kennedy RD, Quinn JE, Johnston PH, et al: BRCA1: Mechanisms of inactivation and implications for management of patients. Lancet 360:1007-1014, 2002 (Pubitemid 35284115)
37. Verhoog LC BC, Seynaeve C, Dahmen G, et al: Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 17:3396-3402, 1999 (Pubitemid 29517906)
38. Brekelmans CTM, Linthorst MA, Seynaeve C, et al: Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1 and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43:867-876, 2007 (Pubitemid 46366688)
39. Kriege M, Seynaeve C, Meijers-Heijboer H, et al: Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients. Breast Cancer Res Treat 111:303-311, 2008
40. Bonadona V, Dussart-Moser S, Voirin N, et al: Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat 101:233-245, 2007 (Pubitemid 46115430)
41. Robson M, Levin D, Federici M, et al: Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91:2112-2117, 1999 (Pubitemid 30019573)
42. Chappuis PO, Kapusta L, Bégin LR, et al: Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 18:4045-4052, 2000 (Pubitemid 32038396)
43. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al: Familial invasive breast cancer: Worse outcome related to BRCA1 mutations. J Clin Oncol 18:4053-4059, 2000 (Pubitemid 32038397)
44. Amat S, Penault-Llorca F, Cure H, et al: Scarff-Bloom Richardson grading: A pleiotropic marker of chemosensitivity in invasive ductal carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 20:791-796, 2002
45. Colleoni M, Minchella I, Mazzarol G, et al: Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 11:1057-1059, 2000
46. Wang J, Buchholz TA, Middleton LP, et al: Assessment of histological features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 94:3107-3114, 2002 (Pubitemid 34685488)